Neoplasm
MONDO:0005070A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.
Also known as: cell process disease, disease of cellular proliferation, neoplasia, neoplasm, neoplasm (disease), neoplastic disease, neoplastic growth, tumor
32492 clinical trials for this condition and its sub-types, 3884 tagged with Neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neoplasm
-
Cancer 2,537 trials · 27,459 incl. sub-types
33 sub-types
- Carcinoma 224 trials · 14,724 incl. sub-types Sub-types →
- Thoracic cancer 61 trials · 8,237 incl. sub-types Sub-types →
- Digestive system cancer 267 trials · 7,054 incl. sub-types Sub-types →
- Respiratory system cancer 6 trials · 4,516 incl. sub-types Sub-types →
- Reproductive system cancer 4 trials · 4,380 incl. sub-types Sub-types →
- Immune system cancer 0 trials · 3,121 incl. sub-types Sub-types →
- Malignant endocrine neoplasm 17 trials · 2,924 incl. sub-types Sub-types →
- Head and neck cancer 637 trials · 2,004 incl. sub-types Sub-types →
- Nervous system cancer 17 trials · 1,996 incl. sub-types Sub-types →
- Musculoskeletal system cancer 2 trials · 1,968 incl. sub-types Sub-types →
- Malignant urinary system neoplasm 75 trials · 1,664 incl. sub-types Sub-types →
- Secondary malignant neoplasm 27 trials · 1,289 incl. sub-types Sub-types →
- High grade malignant neoplasm 0 trials · 1,239 incl. sub-types Sub-types →
- Integumentary system cancer 0 trials · 1,084 incl. sub-types Sub-types →
- Sarcoma 493 trials · 1,026 incl. sub-types Sub-types →
- Malignant soft tissue neoplasm 7 trials · 650 incl. sub-types Sub-types →
- Childhood malignant neoplasm 239 trials · 598 incl. sub-types Sub-types →
- Peritoneum cancer 67 trials · 512 incl. sub-types Sub-types →
- Refractory malignant neoplasm 222 trials · 229 incl. sub-types Sub-types →
- Malignant mixed neoplasm 0 trials · 165 incl. sub-types Sub-types →
- Anaplastic cancer 0 trials · 156 incl. sub-types Sub-types →
- Cardiovascular cancer 0 trials · 153 incl. sub-types Sub-types →
- Malignant mesothelioma 37 trials · 108 incl. sub-types Sub-types →
- Lipomatous cancer 0 trials · 83 incl. sub-types Sub-types →
- Retroperitoneal cancer 3 trials · 82 incl. sub-types Sub-types →
- Malignant germ cell tumor 14 trials · 70 incl. sub-types Sub-types →
- Cancer of unknown primary site 54 trials
- Malignant spindle cell neoplasm 0 trials · 40 incl. sub-types Sub-types →
- Blastoma 0 trials · 4 incl. sub-types Sub-types →
- Malignant giant cell tumor 0 trials · 4 incl. sub-types Sub-types →
- Malignant glomus tumor 1 trial
- Malignant adenoma 0 trials Sub-types →
- Malignant mesenchymoma 0 trials Sub-types →
-
Epithelial neoplasm 22 trials · 15,048 incl. sub-types
24 sub-types
- Carcinoma 224 trials · 14,724 incl. sub-types Sub-types →
- Glandular cell neoplasm 6 trials · 5,266 incl. sub-types Sub-types →
- Squamous cell neoplasm 21 trials · 1,836 incl. sub-types Sub-types →
- Transitional cell neoplasm 0 trials · 699 incl. sub-types Sub-types →
- Ovarian epithelial tumor 14 trials · 664 incl. sub-types Sub-types →
- Epithelial tumor of colon 0 trials · 407 incl. sub-types Sub-types →
- Epithelial neoplasm of rectum 0 trials · 398 incl. sub-types Sub-types →
- Epithelial skin neoplasm 0 trials · 310 incl. sub-types Sub-types →
- Adenoma 27 trials · 249 incl. sub-types Sub-types →
- Papillary epithelial neoplasm 0 trials · 131 incl. sub-types Sub-types →
- Basal cell neoplasm 7 trials · 121 incl. sub-types Sub-types →
- Benign epithelial neoplasm 0 trials · 106 incl. sub-types Sub-types →
- Endometrioid tumor 1 trial · 89 incl. sub-types Sub-types →
- Intraepithelial neoplasia 25 trials · 71 incl. sub-types Sub-types →
- Thymic epithelial neoplasm 14 trials · 56 incl. sub-types Sub-types →
- Epithelial tumor of anal canal 0 trials · 34 incl. sub-types Sub-types →
- Sympathetic paraganglioma 0 trials · 16 incl. sub-types Sub-types →
- Growth hormone-producing pituitary gland neoplasm 0 trials · 5 incl. sub-types Sub-types →
- Myoepithelial tumor 2 trials · 4 incl. sub-types Sub-types →
- Cystic, mucinous, and serous neoplasm 1 trial · 3 incl. sub-types Sub-types →
- Mesonephric neoplasm 1 trial · 3 incl. sub-types Sub-types →
- Wolffian adnexal tumor 0 trials
- Pancreatic delta cell neuroendocrine tumor 0 trials Sub-types →
- Thyroid hyalinizing trabecular adenoma 0 trials
-
Neoplasm of thorax 19 trials · 8,429 incl. sub-types
11 sub-types
- Thoracic cancer 61 trials · 8,237 incl. sub-types Sub-types →
- Breast neoplasm 3,261 trials · 4,628 incl. sub-types Sub-types →
- Lung neoplasm 1,367 trials · 4,039 incl. sub-types Sub-types →
- Neoplasm of mediastinum 7 trials · 196 incl. sub-types Sub-types →
- Thoracic benign neoplasm 0 trials · 22 incl. sub-types Sub-types →
- Heart neoplasm 3 trials · 7 incl. sub-types Sub-types →
- Neoplasm of chest wall 6 trials · 7 incl. sub-types Sub-types →
- Axillary neoplasm 0 trials Sub-types →
- Neoplasm of aortic body 0 trials
- Neoplasm of pericardium 0 trials Sub-types →
- Sternal neoplasm 0 trials Sub-types →
-
Digestive system neoplasm 262 trials · 7,563 incl. sub-types
23 sub-types
- Digestive system cancer 267 trials · 7,054 incl. sub-types Sub-types →
- Intestinal neoplasm 4 trials · 3,074 incl. sub-types Sub-types →
- Hepatobiliary neoplasm 26 trials · 1,772 incl. sub-types Sub-types →
- Pancreatic neoplasm 926 trials · 1,573 incl. sub-types Sub-types →
- Gastric neoplasm 685 trials · 1,101 incl. sub-types Sub-types →
- Neoplasm of esophagus 34 trials · 796 incl. sub-types Sub-types →
- Pharynx neoplasm 1 trial · 505 incl. sub-types Sub-types →
- Oral cavity neoplasm 13 trials · 296 incl. sub-types Sub-types →
- Digestive system neuroendocrine neoplasm 52 trials · 167 incl. sub-types Sub-types →
- Digestive system adenoma 0 trials · 127 incl. sub-types Sub-types →
- Tumor of salivary gland 9 trials · 85 incl. sub-types Sub-types →
- Benign digestive system neoplasm 0 trials · 41 incl. sub-types Sub-types →
- Tongue neoplasm 2 trials · 35 incl. sub-types Sub-types →
- Lip neoplasm 1 trial · 15 incl. sub-types Sub-types →
- Benign epithelial tumor of salivary glands 0 trials · 12 incl. sub-types Sub-types →
- Neoplasm of jaw 1 trial · 9 incl. sub-types Sub-types →
- Odontogenic neoplasm 0 trials · 5 incl. sub-types Sub-types →
- Malignant epithelial tumor of salivary glands 0 trials · 4 incl. sub-types Sub-types →
- Gastrointestinal hamartoma 0 trials · 3 incl. sub-types Sub-types →
- Buccal mucosa neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Gingival neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Neoplasm of floor of mouth 0 trials · 2 incl. sub-types Sub-types →
- Odontoma 0 trials
-
Hematopoietic and lymphoid system neoplasm 692 trials · 6,319 incl. sub-types
9 sub-types
- Hematopoietic and lymphoid cell neoplasm 484 trials · 5,928 incl. sub-types Sub-types →
- Lymphoid hemopathy 0 trials · 4,275 incl. sub-types Sub-types →
- Myeloid hemopathy 0 trials · 1,762 incl. sub-types Sub-types →
- Bone marrow neoplasm 3 trials · 1,631 incl. sub-types Sub-types →
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Spleen neoplasm 0 trials · 232 incl. sub-types Sub-types →
- Lymph node neoplasm 5 trials · 59 incl. sub-types Sub-types →
- STAT3-related early-onset multisystem autoimmune disease 2 trials
- Cavernous hemangioma 1 trial Sub-types →
-
Reproductive system neoplasm 0 trials · 4,651 incl. sub-types
9 sub-types
- Reproductive system cancer 4 trials · 4,380 incl. sub-types Sub-types →
- Female reproductive system neoplasm 27 trials · 2,428 incl. sub-types Sub-types →
- Male reproductive system neoplasm 1 trial · 2,370 incl. sub-types Sub-types →
- Prostate neoplasm 124 trials · 2,225 incl. sub-types Sub-types →
- Benign reproductive system neoplasm 0 trials · 117 incl. sub-types Sub-types →
- Pituitary tumor 23 trials · 83 incl. sub-types Sub-types →
- Sex cord-stromal tumor 4 trials · 14 incl. sub-types Sub-types →
- Brenner tumor 6 trials Sub-types →
- Gonadal tissue neoplasm 0 trials
-
Respiratory tract neoplasm 32 trials · 4,437 incl. sub-types
8 sub-types
- Lung neoplasm 1,367 trials · 4,039 incl. sub-types Sub-types →
- Nasopharyngeal neoplasm 37 trials · 226 incl. sub-types Sub-types →
- Laryngeal neoplasm 72 trials · 138 incl. sub-types Sub-types →
- Pleural neoplasm 5 trials · 97 incl. sub-types Sub-types →
- Bronchial neoplasm 20 trials · 38 incl. sub-types Sub-types →
- Nasal cavity neoplasm 1 trial · 15 incl. sub-types Sub-types →
- SMARCA4-deficient sarcoma of thorax 8 trials
- Trachea neoplasm 2 trials · 5 incl. sub-types Sub-types →
-
Endocrine gland neoplasm 8 trials · 3,332 incl. sub-types
14 sub-types
- Malignant endocrine neoplasm 17 trials · 2,924 incl. sub-types Sub-types →
- Liver and intrahepatic bile duct neoplasm 77 trials · 1,743 incl. sub-types Sub-types →
- Neuroendocrine neoplasm 181 trials · 985 incl. sub-types Sub-types →
- Thyroid tumor 36 trials · 366 incl. sub-types Sub-types →
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Adrenal gland neoplasm 13 trials · 151 incl. sub-types Sub-types →
- Pituitary tumor 23 trials · 83 incl. sub-types Sub-types →
- Benign endocrine neoplasm 0 trials · 60 incl. sub-types Sub-types →
- Tumor of parathyroid gland 3 trials · 46 incl. sub-types Sub-types →
- Functioning endocrine neoplasm 0 trials · 38 incl. sub-types Sub-types →
- Pineal body neoplasm 4 trials · 22 incl. sub-types Sub-types →
- Non-functioning endocrine neoplasm 0 trials · 16 incl. sub-types Sub-types →
- Granulosa cell tumor 2 trials · 6 incl. sub-types Sub-types →
- Familial tumoral calcinosis 1 trial Sub-types →
-
Nervous system neoplasm 8 trials · 2,580 incl. sub-types
7 sub-types
- Nervous system cancer 17 trials · 1,996 incl. sub-types Sub-types →
- Central nervous system neoplasm 51 trials · 1,979 incl. sub-types Sub-types →
- Neuroepithelial neoplasm 6 trials · 1,339 incl. sub-types Sub-types →
- Peripheral nervous system neoplasm 3 trials · 196 incl. sub-types Sub-types →
- Tumor of cranial and spinal nerves 0 trials · 129 incl. sub-types Sub-types →
- Nervous system benign neoplasm 0 trials · 87 incl. sub-types Sub-types →
- Retina neoplasm 2 trials · 36 incl. sub-types Sub-types →
-
Connective tissue neoplasm 1 trial · 2,404 incl. sub-types
13 sub-types
- Bone neoplasm 26 trials · 2,116 incl. sub-types Sub-types →
- Fibroblastic neoplasm 0 trials · 210 incl. sub-types Sub-types →
- Tumor of adipose tissue 1 trial · 98 incl. sub-types Sub-types →
- Chondrosarcoma 39 trials · 44 incl. sub-types Sub-types →
- Tenosynovial giant cell tumor 12 trials · 16 incl. sub-types Sub-types →
- Chondroma 4 trials Sub-types →
- Cholangiolocellular carcinoma 1 trial
- Solitary fibrous tumor/hemangiopericytoma 1 trial
- Angiomyxoma 0 trials
- Cartilage cancer 0 trials
- Dartoic leiomyoma 0 trials
- Lipofibromatosis-like neural tumor 0 trials
- Scirrhous adenocarcinoma 0 trials
-
Head and neck neoplasm 79 trials · 2,200 incl. sub-types
37 sub-types
- Head and neck cancer 637 trials · 2,004 incl. sub-types Sub-types →
- Neoplasm of neck 1 trial · 505 incl. sub-types Sub-types →
- Neoplasm of oropharynx 3 trials · 279 incl. sub-types Sub-types →
- Nasopharyngeal neoplasm 37 trials · 226 incl. sub-types Sub-types →
- Eye neoplasm 3 trials · 192 incl. sub-types Sub-types →
- Skull neoplasm 0 trials · 161 incl. sub-types Sub-types →
- Neoplasm of hypopharynx 0 trials · 100 incl. sub-types Sub-types →
- Tumor of salivary gland 9 trials · 85 incl. sub-types Sub-types →
- Nasal cavity and paranasal sinus neoplasm 0 trials · 44 incl. sub-types Sub-types →
- Tongue neoplasm 2 trials · 35 incl. sub-types Sub-types →
- Lip neoplasm 1 trial · 15 incl. sub-types Sub-types →
- Nasal cavity neoplasm 1 trial · 15 incl. sub-types Sub-types →
- Benign epithelial tumor of salivary glands 0 trials · 12 incl. sub-types Sub-types →
- Recurrent respiratory papillomatosis 8 trials · 9 incl. sub-types Sub-types →
- Cranial nerve neoplasm 0 trials · 8 incl. sub-types Sub-types →
- Tonsil neoplasm 0 trials · 8 incl. sub-types Sub-types →
- Odontogenic neoplasm 0 trials · 5 incl. sub-types Sub-types →
- Malignant epithelial tumor of salivary glands 0 trials · 4 incl. sub-types Sub-types →
- Ocular adnexal lymphoma 4 trials
- Ear neoplasm 0 trials · 3 incl. sub-types Sub-types →
- Buccal mucosa neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Familial thyroglossal duct cyst 2 trials
- Gingival neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Neoplasm of floor of mouth 0 trials · 2 incl. sub-types Sub-types →
- Palatal neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Head and neck paraganglioma 1 trial Sub-types →
- Juvenile nasopharyngeal angiofibroma 1 trial
- Cavernous hemangioma of face 0 trials Sub-types →
- Epignathus 0 trials
- Facial dermoid cyst 0 trials Sub-types →
- Gasserian ganglion meningioma 0 trials
- Laryngeal neuroendocrine neoplasm 0 trials Sub-types →
- Laryngotracheal angioma 0 trials
- Lipoma of face 0 trials Sub-types →
- Nasal cavity and paranasal sinus lethal midline granuloma 0 trials
- Nasal ganglioglioma 0 trials
- Nasal glial heterotopia 0 trials
-
Urinary system neoplasm 21 trials · 1,690 incl. sub-types
8 sub-types
- Malignant urinary system neoplasm 75 trials · 1,664 incl. sub-types Sub-types →
- Kidney neoplasm 59 trials · 860 incl. sub-types Sub-types →
- Urinary bladder neoplasm 65 trials · 699 incl. sub-types Sub-types →
- Urothelial neoplasm 2 trials · 693 incl. sub-types Sub-types →
- Benign urinary system neoplasm 50 trials · 62 incl. sub-types Sub-types →
- Ureter neoplasm 2 trials · 34 incl. sub-types Sub-types →
- Urethra neoplasm 3 trials · 31 incl. sub-types Sub-types →
- Prostate phyllodes tumor 0 trials Sub-types →
-
Virus associated tumor 5 trials · 1,241 incl. sub-types
8 sub-types
- Epstein-Barr virus-related tumor 8 trials · 991 incl. sub-types Sub-types →
- Human papillomavirus-related squamous cell carcinoma 115 trials · 116 incl. sub-types Sub-types →
- Cutaneous neuroendocrine carcinoma 78 trials
- Human herpesvirus 8-related tumor 1 trial · 64 incl. sub-types Sub-types →
- Adult T-cell leukemia/lymphoma 31 trials
- HIV-associated cancer 9 trials
- AIDS-related primary central nervous system lymphoma 3 trials
- Bowenoid papulosis 0 trials
-
Melanocytic neoplasm 2 trials · 1,100 incl. sub-types
3 sub-types
- Melanoma 891 trials · 1,035 incl. sub-types Sub-types →
- Melanocytic skin neoplasm 2 trials · 359 incl. sub-types Sub-types →
- Central nervous system melanocytic neoplasm 1 trial · 4 incl. sub-types Sub-types →
-
Skin neoplasm 168 trials · 990 incl. sub-types
17 sub-types
- Skin cancer 117 trials · 798 incl. sub-types Sub-types →
- Melanocytic skin neoplasm 2 trials · 359 incl. sub-types Sub-types →
- Epithelial skin neoplasm 0 trials · 310 incl. sub-types Sub-types →
- Benign neoplasm of skin 3 trials · 117 incl. sub-types Sub-types →
- Dermis tumor 0 trials · 90 incl. sub-types Sub-types →
- Actinic keratosis 41 trials
- Epidermal appendage tumor 3 trials · 8 incl. sub-types Sub-types →
- Eyelid neoplasm 3 trials · 7 incl. sub-types Sub-types →
- Schwannomatosis 3 trials Sub-types →
- Maffucci syndrome 2 trials
- Benign dermal neurilemmoma 0 trials
- Calcifying epithelial odontogenic tumor 0 trials
- Dermoid cyst of skin 0 trials
- Familial Dupuytren contracture 0 trials
- Familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome 0 trials
- Familial multiple discoid fibromas 0 trials
- Hemangiopericytoma of skin 0 trials
-
Connective and soft tissue neoplasm 10 trials · 824 incl. sub-types
3 sub-types
- Soft tissue neoplasm 23 trials · 740 incl. sub-types Sub-types →
- Benign connective and soft tissue neoplasm 0 trials · 101 incl. sub-types Sub-types →
- Synovial chondromatosis 0 trials
-
Benign neoplasm 13 trials · 690 incl. sub-types
29 sub-types
- Musculoskeletal system benign neoplasm 0 trials · 224 incl. sub-types Sub-types →
- Integumentary system benign neoplasm 0 trials · 120 incl. sub-types Sub-types →
- Benign reproductive system neoplasm 0 trials · 117 incl. sub-types Sub-types →
- Cardiovascular organ benign neoplasm 0 trials · 114 incl. sub-types Sub-types →
- Benign epithelial neoplasm 0 trials · 106 incl. sub-types Sub-types →
- Nervous system benign neoplasm 0 trials · 87 incl. sub-types Sub-types →
- Benign urinary system neoplasm 50 trials · 62 incl. sub-types Sub-types →
- Benign endocrine neoplasm 0 trials · 60 incl. sub-types Sub-types →
- Pheochromocytoma 59 trials Sub-types →
- Benign digestive system neoplasm 0 trials · 41 incl. sub-types Sub-types →
- Thoracic benign neoplasm 0 trials · 22 incl. sub-types Sub-types →
- Benign perivascular tumor 0 trials · 18 incl. sub-types Sub-types →
- Respiratory system benign neoplasm 1 trial · 8 incl. sub-types Sub-types →
- Benign neoplasm of salivary gland 1 trial · 5 incl. sub-types Sub-types →
- Benign chondrogenic neoplasm 0 trials · 4 incl. sub-types Sub-types →
- Benign neoplasm of oral cavity 1 trial Sub-types →
- Benign mastocytoma 0 trials
- Benign mesenchymoma 0 trials
- Benign mesothelioma 0 trials Sub-types →
- Benign neoplasm of buccal mucosa 0 trials Sub-types →
- Benign neoplasm of floor of mouth 0 trials
- Benign neoplasm of lip 0 trials
- Benign neoplasm of neck 0 trials
- Benign neoplasm of pharynx 0 trials Sub-types →
- Benign phyllodes tumor 0 trials Sub-types →
- Calcifying fibrous tumor 0 trials
- Germ cell benign neoplasm 0 trials Sub-types →
- Immune system organ benign neoplasm 0 trials Sub-types →
- Peritoneal benign neoplasm 0 trials Sub-types →
-
Childhood neoplasm 46 trials · 649 incl. sub-types
14 sub-types
- Childhood malignant neoplasm 239 trials · 598 incl. sub-types Sub-types →
- Childhood infratentorial neoplasm 1 trial · 109 incl. sub-types Sub-types →
- Childhood kidney neoplasm 1 trial · 30 incl. sub-types Sub-types →
- Childhood ependymoma 7 trials Sub-types →
- Childhood germ cell tumor 3 trials · 7 incl. sub-types Sub-types →
- Childhood astrocytic tumor 1 trial · 2 incl. sub-types Sub-types →
- Childhood adrenal gland pheochromocytoma 1 trial
- Childhood choroid plexus neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Childhood optic nerve glioma 1 trial
- Childhood spinal cord tumor 1 trial
- Childhood carcinoid tumor 0 trials
- Childhood mediastinal neurogenic neoplasm 0 trials
- Childhood testicular neoplasm 0 trials Sub-types →
- Pediatric meningioma 0 trials Sub-types →
-
Peritoneal neoplasm 63 trials · 522 incl. sub-types
4 sub-types
- Peritoneum cancer 67 trials · 512 incl. sub-types Sub-types →
- Peritoneal mesothelioma 14 trials · 22 incl. sub-types Sub-types →
- Peritoneal benign neoplasm 0 trials Sub-types →
- Peritoneal solitary fibrous tumor 0 trials Sub-types →
-
Embryonal neoplasm 9 trials · 462 incl. sub-types
12 sub-types
- Primitive neuroectodermal tumor 14 trials · 228 incl. sub-types Sub-types →
- Ewing sarcoma/peripheral primitive neuroectodermal tumor 7 trials · 149 incl. sub-types Sub-types →
- Medulloblastoma 110 trials Sub-types →
- Rhabdoid tumor 63 trials · 75 incl. sub-types Sub-types →
- Wilms tumor 60 trials · 63 incl. sub-types Sub-types →
- Hepatoblastoma 42 trials Sub-types →
- Notochordal tumor 0 trials · 34 incl. sub-types Sub-types →
- Pineoblastoma 15 trials Sub-types →
- Blastoma 0 trials · 4 incl. sub-types Sub-types →
- Congenital mesoblastic nephroma 2 trials Sub-types →
- Testicular embryonal carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Intraocular medulloepithelioma 1 trial
-
Mesenchymal cell neoplasm 0 trials · 351 incl. sub-types
6 sub-types
- Fibroblastic neoplasm 0 trials · 210 incl. sub-types Sub-types →
- Myomatous neoplasm 1 trial · 188 incl. sub-types Sub-types →
- Tumor of adipose tissue 1 trial · 98 incl. sub-types Sub-types →
- Pericytic neoplasm 1 trial · 24 incl. sub-types Sub-types →
- Chondrogenic neoplasm 1 trial · 4 incl. sub-types Sub-types →
- Osteogenic neoplasm 0 trials Sub-types →
-
Cardiovascular neoplasm 0 trials · 277 incl. sub-types
5 sub-types
- Vascular neoplasm 3 trials · 271 incl. sub-types Sub-types →
- Cardiovascular cancer 0 trials · 153 incl. sub-types Sub-types →
- Cardiovascular organ benign neoplasm 0 trials · 114 incl. sub-types Sub-types →
- Heart neoplasm 3 trials · 7 incl. sub-types Sub-types →
- Neoplasm of pericardium 0 trials Sub-types →
-
Mixed neoplasm 0 trials · 192 incl. sub-types
10 sub-types
- Malignant mixed neoplasm 0 trials · 165 incl. sub-types Sub-types →
- Mixed glioma 6 trials · 20 incl. sub-types Sub-types →
- Ovarian seromucinous tumor 1 trial · 14 incl. sub-types Sub-types →
- Uterine corpus mixed epithelial and mesenchymal neoplasm 0 trials · 14 incl. sub-types Sub-types →
- Fibroepithelial neoplasm 0 trials · 12 incl. sub-types Sub-types →
- Pleomorphic adenoma 12 trials
- Eccrine mixed tumor of skin 0 trials
- Mixed cell adenoma 0 trials Sub-types →
- Mixed epithelial stromal tumor 0 trials Sub-types →
- Mixed germ cell-sex cord-stromal tumor 0 trials Sub-types →
-
Mesothelial neoplasm 2 trials · 179 incl. sub-types
1 sub-type
- Mesothelioma 94 trials · 178 incl. sub-types Sub-types →
-
Germ cell tumor 57 trials · 125 incl. sub-types
13 sub-types
- Malignant germ cell tumor 14 trials · 70 incl. sub-types Sub-types →
- Gonadal germ cell tumor 0 trials · 52 incl. sub-types Sub-types →
- Nongerminomatous germ cell tumor 12 trials · 33 incl. sub-types Sub-types →
- Extragonadal germ cell tumor 2 trials · 29 incl. sub-types Sub-types →
- Germinomatous germ cell tumor 1 trial · 22 incl. sub-types Sub-types →
- Ovarian germ cell tumor 9 trials · 13 incl. sub-types Sub-types →
- Childhood germ cell tumor 3 trials · 7 incl. sub-types Sub-types →
- Choriocarcinoma 4 trials · 5 incl. sub-types Sub-types →
- Adult germ cell tumor 0 trials Sub-types →
- Fallopian tube germ cell tumor 0 trials Sub-types →
- Germ cell benign neoplasm 0 trials Sub-types →
- Germ cell tumor of the vulva 0 trials Sub-types →
- Retroperitoneal germ cell neoplasm 0 trials
-
Retroperitoneal neoplasm 3 trials · 84 incl. sub-types
5 sub-types
- Retroperitoneal cancer 3 trials · 82 incl. sub-types Sub-types →
- Retroperitoneal germ cell neoplasm 0 trials
- Retroperitoneal hemangiopericytoma 0 trials
- Retroperitoneal inflammatory myofibroblastic tumor 0 trials
- Retroperitoneal neuroblastoma 0 trials Sub-types →
-
Histiocytoma 0 trials · 49 incl. sub-types
3 sub-types
- Undifferentiated pleomorphic sarcoma 48 trials Sub-types →
- Benign fibrous histiocytoma 1 trial · 2 incl. sub-types Sub-types →
- Histiocytoma, Angiomatoid fibrous 2 trials
-
Pre-malignant neoplasm 2 trials · 43 incl. sub-types
1 sub-type
- Actinic keratosis 41 trials
-
Spindle cell neoplasm 1 trial · 40 incl. sub-types
5 sub-types
- Malignant spindle cell neoplasm 0 trials · 40 incl. sub-types Sub-types →
- Spindle cell melanoma 0 trials · 1 incl. sub-types Sub-types →
- Spindle cell hemangioma 0 trials
- Spindle cell lipoma 0 trials
- Spindle cell nevus 0 trials
-
RET fusion positive cancer 20 trials
-
Giant cell tumor 1 trial · 20 incl. sub-types
2 sub-types
- Tenosynovial giant cell tumor 12 trials · 16 incl. sub-types Sub-types →
- Malignant giant cell tumor 0 trials · 4 incl. sub-types Sub-types →
-
NTRK fusion positive cancer 19 trials
-
Upper aerodigestive tract neoplasm 18 trials
-
Cystic neoplasm 0 trials · 17 incl. sub-types
3 sub-types
- Cystadenoma 0 trials · 11 incl. sub-types Sub-types →
- Cystadenocarcinoma 0 trials · 6 incl. sub-types Sub-types →
- Papillary cystic neoplasm 0 trials Sub-types →
-
Trophoblastic neoplasm 1 trial · 15 incl. sub-types
4 sub-types
- Gestational trophoblastic neoplasm 7 trials · 8 incl. sub-types Sub-types →
- Choriocarcinoma 4 trials · 5 incl. sub-types Sub-types →
- Hydatidiform mole 3 trials · 5 incl. sub-types Sub-types →
- Testicular trophoblastic tumor 0 trials · 1 incl. sub-types Sub-types →
-
Odontogenic cyst 11 trials · 12 incl. sub-types
1 sub-type
- Dentigerous cyst 2 trials
-
Erythroplakia 8 trials
-
Epidural spinal canal neoplasm 3 trials · 5 incl. sub-types
2 sub-types
-
Hamartoma 1 trial · 5 incl. sub-types
13 sub-types
- Gastrointestinal hamartoma 0 trials · 3 incl. sub-types Sub-types →
- Linear nevus sebaceous syndrome 1 trial
- Angiomyomatous hamartoma 0 trials
- Basaloid follicular hamartoma 0 trials
- Chondroid hamartoma 0 trials
- Congenital epulis 0 trials
- Congenital smooth muscle hamartoma 0 trials
- Giant mammary hamartoma 0 trials
- Hamartoma of lung 0 trials Sub-types →
- Hamartoma of skin appendage 0 trials Sub-types →
- Linear and whorled nevoid hypermelanosis 0 trials
- Mesenchymal hamartoma 0 trials Sub-types →
- Odontoma 0 trials
-
Thyroglossal duct cyst 3 trials
1 sub-type
- Familial thyroglossal duct cyst 2 trials
-
Phosphaturic mesenchymal tumor 1 trial
-
Mesenchymoma 0 trials
2 sub-types
- Benign mesenchymoma 0 trials
- Malignant mesenchymoma 0 trials Sub-types →
-
Nail tumor 0 trials
3 sub-types
- Onychocytic matricoma 0 trials
- Onychomatricoma 0 trials
- Subungual glomus tumor 0 trials
-
Non-seminomatous lesion 0 trials
-
Skeletal muscle neoplasm 0 trials
2 sub-types
- Benign skeletal muscle neoplasm 0 trials
- Skeletal muscle cancer 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 778 trials in this tab.
-
Custom-Built immune cells take aim at a notorious cancer mutation
Cure OngoingResearchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Can a simpler scope technique match the complex one for large colon growths?
Disease control OngoingResearchers compare two ways to remove large, non-cancerous growths from the colon. One method, endoscopic mucosal resection, removes the growth in pieces. The other, endoscopic submucosal dissection, removes it in one piece but takes longer and carries more risk. The trial tests…
Sponsor: José Carlos Marín Gabriel • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immune cells take on tough tumors in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…
Phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug combo enters human testing
Disease control OngoingThis early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control By invitation onlyThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Lifeline for ALK cancer patients: continued access to ceritinib
Disease control OngoingThis study offers continued treatment with the drug ceritinib to people with ALK-positive cancers who were already benefiting from it in a previous Novartis study. The main goal is to track safety and side effects over time. About 233 participants will receive the drug as long as…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Liver tumor treatment gets a targeted boost: Drug-Loaded beads take aim at metastases
Disease control OngoingThis early-phase trial is testing a new approach for people with liver metastases (cancer that has spread to the liver from elsewhere). Doctors are using a procedure called TACE to deliver the drug bevacizumab directly into the liver's blood vessels, aiming to concentrate the tre…
Phase 1/2 • Sponsor: Pardis Noor Medical Imaging and Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Radiation probe targets Hard-to-Treat tumors
Disease control By invitation onlyResearchers are testing a new molecular probe called 177Lu-NI-FAPI that aims to deliver radiation directly to tumor cells. The probe targets two features common in aggressive tumors: low oxygen levels and fibroblast activation proteins. The study enrolls up to 20 adults with adva…
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Drug could slash surgeries for rare airway disease
Disease control OngoingThis phase II trial tests whether bevacizumab, a drug that blocks blood vessel growth, can lengthen the time between surgeries for adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants receive 11 doses of t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail shows promise in early cancer trial
Disease control OngoingThis phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug targets Sugar-Coated proteins on cancer cells
Disease control OngoingResearchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…
Phase 1 • Sponsor: Phost'In Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New antibody aims to preserve immune checkpoint while fighting cancer
Disease control OngoingResearchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise in battling recurrent ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Outpatient immunotherapy tested for hard-to-treat lymphomas
Disease control OngoingResearchers are testing an experimental drug called epcoritamab in adults with diffuse large B-cell lymphoma or classic follicular lymphoma that has come back or stopped responding to earlier treatments. The trial gives the drug as an injection under the skin in increasing doses,…
Phase 2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immune cell combo takes on tough melanoma
Disease control OngoingThis early-phase trial tests a new treatment for people with advanced melanoma that has stopped responding to standard immunotherapy. The treatment uses a patient's own immune cells (TILs) that have been engineered to produce a protein called IL15, combined with a drug called ace…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Dual-Action antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an antibody drug boost standard chemotherapy against an aggressive blood cancer?
Disease control OngoingDiffuse large B-cell lymphoma is an aggressive cancer of immune cells called B cells. This phase 3 trial tests whether adding an experimental antibody drug called epcoritamab to the standard R-CHOP chemotherapy combination improves disease control compared with R-CHOP alone. Abou…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Immune-Boosting drug takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…
Phase 1 • Sponsor: Tizona Therapeutics, Inc • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New triple therapy targets FLT3-Mutated leukemia in frail patients
Disease control OngoingThis study tests a combination of three drugs—gilteritinib, venetoclax, and azacitidine—in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a FLT3 gene change. Participants are older or have other health issues that prevent them from receiv…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New antibody tested against aggressive blood cancer
Disease control OngoingResearchers are testing an experimental drug called epcoritamab in Chinese adults with B-cell non-Hodgkin lymphoma. The trial gives epcoritamab alone or combines it with standard chemotherapy drugs (R-CHOP or R2). The main goals are to check safety and see how well the cancer res…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immunotherapy injection tested against Hard-to-Treat childhood lymphoma
Disease control OngoingStandard treatment cures most children with aggressive mature B-cell lymphomas, but those whose cancer returns or resists therapy have few options. This phase 1b trial tests epcoritamab, an experimental immunotherapy given as an injection under the skin, in children and young adu…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Phase 1/2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Sound waves take aim at pancreatic tumors: new trial tests HIFU
Disease control PausedThis trial tests a procedure called High-Intensity Focused Ultrasound (HIFU) for people with pancreatic cancer that cannot be removed by surgery. The study has two parts: first, checking how safe the procedure is, and second, seeing if it helps patients live longer. About 26 part…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for certain cancers
Disease control OngoingThis study tests whether giving immunotherapy before surgery can help people with MSI/dMMR tumors. The goal is to shrink or eliminate the tumor before it is removed, potentially improving survival. The trial includes adults with localized, resectable cancers such as colorectal, g…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New pill hopes to tame rare blood cancer in japanese patients
Disease control OngoingThis study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how ma…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Personalized dosing of cancer drug pazopanib tested in early trial
Disease control OngoingThis phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if t…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Sound waves open brain barrier to attack deadly tumor
Disease control PausedThis early study tests a combination approach for recurrent glioblastoma, an aggressive brain cancer. The treatment uses focused ultrasound (NaviFUS) to temporarily open the blood-brain barrier, allowing the drug Avastin (bevacizumab) to reach the tumor more effectively. Ten adul…
Phase 1/2 • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill combo aims to tame Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a radioactive antibody seek out and destroy Hard-to-Treat tumors?
Disease control Expanded access (paused)This program provides access to an investigational therapy called MNPR-101-PCTA-177Lu for people with advanced solid tumors that have not responded to existing treatments. The therapy combines an antibody with a radioactive payload, designed to bind to a protein called uPAR found…
Sponsor: Monopar Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase 1/2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Personalized cancer attack: new trial matches drugs to tumor genes
Disease control OngoingThis phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo shows promise for hard-to-treat HER2 cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for advanced cancer: KQB198 trial launches
Disease control OngoingThis early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have not responded to other treatments. The study aims to find a safe dose and see if KQB198 can shrink tumors when used alone or with other cancer drugs. About 100 participants will t…
Phase 1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New cancer drug saruparib enters early human testing
Disease control OngoingThis early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control OngoingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New liposome chemo shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new gemcitabine formulation outsmart advanced solid tumors?
Disease control OngoingThis phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a cocktail of immune boosters shrink Hard-to-Treat tumors?
Disease control OngoingThis phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
Disease control OngoingThis phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…
Phase 1/2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat cancers with BRAF mutation
Disease control OngoingThis early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare tumors: tarlatamab trial opens
Disease control OngoingThis study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Cancer drug brigimadlin tested for Long-Term use in solid tumour patients
Disease control OngoingThis study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a smart drug deliver a One-Two punch to advanced cancers?
Disease control PausedThis trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …
Phase 1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug duo aims to shrink hard-to-treat tumors
Disease control OngoingThis early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill combo takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Breast cancer patients monitored for years in new safety trial
Disease control By invitation onlyThis study looks at the long-term safety of a drug called TOL2506, which suppresses ovarian function, in people with hormone receptor-positive (HR+) breast cancer. It includes premenopausal women and men who already completed a previous study. Participants will take TOL2506 along…
Phase 3 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug combo shows promise for hard-to-treat stomach cancer
Disease control OngoingThis study tests a drug called zolbetuximab that targets a protein (CLDN18.2) found in many stomach and gastroesophageal junction tumors. The drug is given alone or with chemotherapy and/or immunotherapy to see how well it controls tumor growth. The study includes 143 adults with…
Phase 2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New program helps cancer survivors fight heart disease with exercise
Disease control OngoingThis study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Diet and exercise may keep cancer patients stronger during chemo
Disease control OngoingThis study tests whether early, personalized nutritional support and a simple home exercise program can prevent weight loss and improve quality of life in 200 adults with lung, colorectal, ovarian, or pancreatic cancer starting palliative chemotherapy. Participants receive guidan…
Sponsor: Gødstrup Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThis study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Laser and radiation combo takes on recurrent brain tumors
Disease control OngoingThis pilot study is testing a two-step treatment for people whose gliomas (a type of brain tumor) have come back after standard therapy. First, doctors use a laser guided by MRI to destroy as much tumor as possible. Then, they give a short course of focused radiation. The main go…
Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New vaccine aims to stop colorectal cancer recurrence in High-Risk patients
Disease control OngoingThis study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control By invitation onlyThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a simple shot replace IV drips for some cancer patients?
Disease control OngoingThis early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug ABBV-319 takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests an investigational drug called ABBV-319 in about 154 adults with certain B-cell cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The study has two…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
Disease control OngoingThis early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …
Phase 1/2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo therapy targets liver cancer in clinical trial
Disease control OngoingThis study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…
Phase 2 • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Radioactive microspheres aimed at prostate cancer: early safety trial underway
Disease control OngoingThis early study tests the safety of TheraSphere PCa, tiny radioactive glass beads injected into the prostate to treat localized prostate cancer. The trial involves 36 men with favorable intermediate-risk cancer and aims to find the maximum safe radiation dose. Researchers will m…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New pill takes on tough cancers in first human test
Disease control OngoingThis early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…
Phase 1 • Sponsor: Circle Pharma • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Cancer drug regorafenib gets a second chance in small continuation study
Disease control OngoingThis study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug dostarlimab shows promise in early trial for advanced cancers
Disease control OngoingThis early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…
Phase 1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets rare gene fusions in multiple cancers
Disease control OngoingThis phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Dual-Action drug outsmart advanced cancers?
Disease control OngoingThis early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Experimental drug combo tested for rare, deadly castleman disease
Disease control OngoingThis study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New cancer pill tested in patients with no other options
Disease control OngoingThis early-stage study tested the safety of an experimental cancer drug called AZD6244, given as a capsule, in 58 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check for side effects and how the drug moves through the b…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Triple-Drug punch before surgery beat melanoma recurrence?
Disease control OngoingThis trial is testing three different drug combinations given before surgery for advanced melanoma. The goal is to see which combination best shrinks the tumor before it is removed and helps prevent the cancer from coming back after surgery. The study involves adults with resecta…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
Disease control By invitation onlyThis extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …
Phase 3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can radiation plus two immunotherapies shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing whether combining targeted radiation (SBRT) with two immunotherapy drugs—nivolumab and an experimental anti-IL-8 antibody—is safe and potentially effective for people with advanced solid tumors or melanoma that have stopped responding to standard…
Phase 1 • Sponsor: Yana Najjar • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…
Phase 1/2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Cancer patients to continue promising treatments in major extension trial
Disease control By invitation onlyThis long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New combo therapy shows promise for common lung cancer mutation
Disease control OngoingThis study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new biologic boost standard brain cancer therapy?
Disease control OngoingThis trial is testing whether adding an experimental drug called XS005 to the standard chemotherapy regimen (Stupp) is safe and shows promise for people with glioblastoma, an aggressive brain tumor. The study involves 13 adults aged 18 to 70 who will receive XS005 infusions over …
Phase 1/2 • Sponsor: Dushu Lake Hospital Affiliated to Soochow University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Radioactive drug takes on brain cancer in early trial
Disease control OngoingThis early-phase trial is testing a radioactive drug called 131I-TLX101, given alongside standard care, for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study involves 12 participants and aims to find the safest dose and check for side effects. It is …
Phase 1 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Parents key to fighting obesity in childhood cancer survivors
Disease control OngoingThis study tests a program that teaches parents how to help their child, a childhood cancer survivor, eat healthy and exercise more. The goal is to prevent or reduce obesity, which is a major risk for heart disease in these children. About 520 families will take part in one of tw…
Sponsor: University of South Florida • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
Disease control OngoingThis phase II trial is investigating whether giving immunotherapy before surgery can boost the immune system's attack on head and neck squamous cell carcinoma. Participants receive atezolizumab alone or combined with other immune-modulating agents, then undergo surgery. The study…
Phase 2 • Sponsor: Alain Algazi • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat cancers
Disease control OngoingThis study tests a new treatment using a patient's own immune cells that are genetically modified to better recognize and attack certain solid tumors. It is for people with advanced cancers like synovial sarcoma that have not responded to other treatments. The goal is to see if t…
Phase 2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill rouse the immune system against pancreatic cancer?
Disease control CancelledThis early-phase trial is testing whether an experimental oral drug called BXCL701 can change how the immune system responds to pancreatic cancer. The study will enroll people with untreated, locally advanced or metastatic pancreatic cancer who can undergo tumor biopsies before a…
Early phase 1 • Sponsor: BioXcel Therapeutics Inc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shrink advanced tumors? a new drug steps into the spotlight
Disease control OngoingThis early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer patients who respond to drug get continued access in new study
Disease control By invitation onlyThis study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill targets rare cancer drivers in chinese patients
Disease control OngoingThis phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a shorter chemo combo tame High-Risk neuroblastoma?
Disease control OngoingThis pilot study is testing a new, shortened chemotherapy regimen called N9 for children with high-risk neuroblastoma, a type of cancer. The regimen combines several chemotherapy drugs given in different cycles to see if it is safe and effective. The study includes children under…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a walking routine alter cancer biomarkers? new trial investigates
Disease control OngoingThis study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Cancer patients monitored for years after experimental immune cell treatment
Disease control By invitation onlyThis study follows 60 cancer patients who have already received SynKIR CAR T cell therapy to check for long-term side effects and see how well the treatment continues to work. Researchers will monitor for delayed reactions and measure survival over time. The goal is to understand…
Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for lymphoma patients: drug combo aims to keep cancer at bay longer
Disease control OngoingThis study tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) works better than standard chemoimmunotherapy for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,095 adults will be randomly assi…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingThis trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …
Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Cancer drug spartalizumab gets extended safety check in ongoing patients
Disease control OngoingThis study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat eye cancer?
Disease control OngoingThis trial tests an experimental drug called DYP688 in people with metastatic uveal melanoma, a rare eye cancer that has spread, and other melanomas with specific genetic mutations. The study aims to find a safe dose and see whether the drug can shrink tumors. Participants receiv…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New combo therapy aims to shrink tumors in hard-to-treat cancers
Disease control OngoingThis study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Cancer patients get extended access to promising immunotherapy
Disease control OngoingThis study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a targeted pill slow brain tumor growth after surgery?
Disease control ApprovedThis expanded access program offers vorasidenib, an oral drug, to people aged 12 and older with IDH-mutated glioma who have had surgery. The drug targets specific genetic mutations in tumor cells. The goal is to see if it can help control the disease without immediate need for ra…
Sponsor: Servier • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental drug SHR-A2009 takes first steps against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo shows promise against tough stomach cancer
Disease control OngoingThis study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer without their cancer growing. About 500 adults…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New immunotherapy combo may save bladders in cancer patients
Disease control OngoingThis phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, given before surgery for stage II-IIIa bladder cancer. The goal is to see if the combination can eliminate the tumor, allowing patients to keep their bladder instead of having it removed. About 90 partici…
Phase 2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill combo aims to outsmart resistant breast cancer
Disease control OngoingThis phase 3 trial tests whether switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor can delay cancer progression better than staying on standard aromatase inhibitor therapy in people with HR+/HER2- metastatic breast cancer who have an ESR1 mutation. About 315 particip…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Phase 1/2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New program aims to protect cancer Patients' hearts during treatment
Disease control By invitation onlyThis study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …
Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug shows promise against multiple Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Phase 1/2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at multiple Hard-to-Treat cancers
Disease control CancelledThis study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for tough lung cancer: tarlatamab trial targets advanced disease
Disease control OngoingThis study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. Researchers will also monitor side effects and how long any response l…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Cancer patients get continued access to lifesaving drug in new study
Disease control OngoingThis study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo aims to outsmart recurring lymphoma
Disease control OngoingThis phase 3 trial tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) helps adults with follicular lymphoma that has returned or not responded to previous treatment. Participants receive either the standard therapy alone or …
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental drug COH29 targets tumor growth enzyme in advanced cancers
Disease control OngoingThis early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Pushing a weighted sled may help cancer patients build muscle and lose fat
Disease control OngoingThis pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Cancer patients get continued access to key therapy in extension study
Disease control OngoingThis study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with PI3K mutation
Disease control OngoingThis early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…
Phase 1 • Sponsor: OnKure, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New cancer combo aims to shrink Hard-to-Treat tumors
Disease control OngoingThis study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental drug opens door for rare sarcoma patients with no options left
Disease control Expanded access (ended)This program provides tazemetostat, an experimental drug taken as a pill twice daily, to adults with advanced epithelioid sarcoma—a rare cancer—who have no satisfactory alternative treatments. It is designed for people who cannot join other clinical studies or access the drug thr…
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Cancer drug safety tracked over years in ongoing study
Disease control OngoingThis study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Sound waves zap kidney tumors in new Non-Invasive trial
Disease control OngoingThis study tests a device that uses focused sound waves (histotripsy) to break apart kidney tumors without making any cuts. About 67 adults with a single small kidney mass (3 cm or less) that hasn't spread will be treated. The goal is to see if the tumors are completely gone afte…
Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Hope for aggressive lymphoma: targeted drug added to chemo in major trial
Disease control OngoingThis Phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a specific, aggressive type of lymphoma (non-GCB DLBCL) live longer without their cancer getting worse. About 611 adults aged 18 to 75 who have not been tre…
Phase 3 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for leiomyosarcoma: drug combo trial aims to slow tumor growth
Disease control OngoingThis phase 3 trial tests whether adding lurbinectedin to standard doxorubicin chemotherapy helps people with metastatic leiomyosarcoma live longer without their cancer growing. About 469 adults who have not had prior treatment for advanced disease are being studied. The main goal…
Phase 3 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered virus targets Hard-to-Treat cancers in early trial
Disease control By invitation onlyThis early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…
Early phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…
Phase 1/2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Drug-Radiation combo tame brain tumors?
Disease control PausedThis study tests whether adding the drug azeliragon to targeted radiation therapy can safely shrink brain tumors and keep them under control longer. It involves 46 adults with cancer that has spread to the brain. The goal is to improve tumor control without causing serious side e…
Phase 1/2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lifeline for cancer patients: continued access to promising drug olaparib
Disease control OngoingThis study offers continued treatment with the drug olaparib to people with ovarian or breast cancer who have already seen benefits from it in a previous study. The goal is to keep providing the drug safely while monitoring for any serious side effects. About 185 participants wil…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests whether a combination of two targeted drugs (encorafenib and cetuximab), given alone or with chemotherapy, works better than standard chemotherapy for people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation) that has spread and hasn…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Surgery vs. diet: which tames diabetes better?
Disease control OngoingThis study compares two types of weight-loss surgery (gastric bypass and gastric banding) with an intensive diet and exercise program for controlling type 2 diabetes in moderately obese adults aged 25 to 55. The goal is to see which approach works best for improving diabetes and …
Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo targets Hard-to-Treat brain tumors
Disease control OngoingThis study investigates whether combining ACT001 (an oral drug) with pembrolizumab (an immunotherapy) can help people with recurrent glioblastoma, an aggressive brain cancer. Participants take the drugs before surgery to remove their tumor, allowing researchers to analyze how the…
Phase 1/2 • Sponsor: Accendatech USA Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could extra white cells boost immune recovery in kids with tough leukemia?
Disease control OngoingThis study looks at whether giving children with hard-to-cure leukemia a transfusion of white blood cells (granulocytes) after a cord blood transplant helps their new immune system grow faster and safer. About 40 children under 16 will receive this extra transfusion, and research…
Sponsor: University of Manchester • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo aims to fight lung cancer without chemo
Disease control OngoingThis study tests whether two immunotherapy drugs, balstilimab and botensilimab, are safe and effective as a first treatment for people with metastatic non-small cell lung cancer. The trial includes 45 participants who have not had prior treatment for advanced disease. Researchers…
Phase 2 • Sponsor: Immune Oncology Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Supercharged immune cells aim to stop lymphoma comeback
Disease control OngoingThis early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Zapping just a few spots: new hope for patients with worsening metastatic cancer?
Disease control OngoingThis study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy targets Hard-to-Treat cancers with genetic marker
Disease control OngoingThis early-stage trial is testing a new drug called anvumetostat, given together with other standard chemotherapy drugs, for people with advanced cancers of the digestive system (stomach, bile ducts, or pancreas) that have a specific genetic change called MTAP deletion. The main …
Phase 1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail aims to stall ovarian cancer recurrence
Disease control OngoingThis Phase 3 trial is testing whether adding mirvetuximab soravtansine (a drug that targets a protein called FRα on cancer cells) to standard bevacizumab maintenance therapy can delay cancer progression in women with recurrent ovarian, fallopian tube, or peritoneal cancer. The st…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Virus therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…
Phase 1 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo aims to stop lung Cancer's return
Disease control OngoingThis phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable …
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Blood cancer drug venetoclax gets Long-Term safety check
Disease control OngoingThis study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail aims to boost remission in rare blood cancer
Disease control OngoingThis Phase 2 trial tests whether adding carfilzomib to ibrutinib improves outcomes for people with Waldenström's macroglobulinemia, a rare blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if the combo leads to higher r…
Phase 2 • Sponsor: Christian Buske • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase 1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
E-cigarettes offered to cancer patients who refuse to quit smoking
Disease control By invitation onlyThis study looks at whether giving e-cigarettes to cancer patients who smoke—and who have turned down standard quitting help—can help them switch away from regular cigarettes. About 208 adults with cancer will either receive an e-cigarette and support to switch, or standard care …
Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Antibody-Chemo combo shows promise in slowing stomach cancer
Disease control OngoingThis Phase 3 trial tests whether adding zolbetuximab, an antibody that targets the Claudin 18.2 protein found on many stomach tumors, to standard chemotherapy can delay cancer progression in people with advanced stomach or gastroesophageal junction cancer. About 565 adults whose …
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immune cells injected into brain tumors: a new hope for kids?
Disease control PausedThis early-phase trial tests whether natural killer (NK) cells from healthy donors can be safely injected into the brain tumors of children and young adults whose cancer has returned or is growing. The NK cells are specially treated to resist the tumor's defenses. The main goals …
Phase 1 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Transplant patients with skin cancer get new hope from engineered virus
Disease control OngoingThis study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…
Phase 1/2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo tested for advanced cancers
Disease control OngoingThis early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Cancer patients get continued access to promising drug
Disease control OngoingThis study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Cancer drug combo trial pulled before it even started
Disease control CancelledThis was a planned Phase 2 trial to test two immunotherapy drugs—monalizumab and MEDI5752—in people with metastatic cancers that have a specific genetic feature called MSI/dMMR. The study was withdrawn before enrolling any participants, so no data or results are available. The go…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control CancelledThis was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control CancelledThis was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Phase 2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising combo aims to tame relapsed childhood cancers
Disease control OngoingThis study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New study aims to help cancer survivors manage other health problems
Disease control OngoingThis study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …
Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental cancer combo aims to supercharge immune attack on tumors
Disease control OngoingThis early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…
Phase 1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…
Phase 1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered immune cells take aim at blood cancers
Disease control OngoingThis early-phase study tests a new treatment for people with certain B-cell blood cancers (lymphoma, ALL, or CLL) that have returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack cancer ce…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New microwave tool targets lung tumors without surgery
Disease control OngoingThis study tests a new device that uses microwave energy to destroy small lung tumors. The device is inserted through a bronchoscope, avoiding the need for open surgery. The trial will enroll 35 people with lung nodules that are cancerous or highly suspicious, and who cannot have…
Sponsor: Creo Medical Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Frozen testicle tissue may help infertile men have kids
Disease control OngoingThis experimental study tests whether frozen-thawed testis tissue, when grafted under the skin, can produce sperm in men with infertility. Five men will receive their own stored tissue. The goal is to see if viable sperm can be retrieved, potentially offering a future fertility o…
Sponsor: Herlev and Gentofte Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Phase 1/2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New injection aims to halt ovarian function in breast cancer fight
Disease control OngoingThis phase 3 study tests a 3-month injection (TOL2506) to temporarily stop ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The goal is to see if it works well with hormone therapy (tamoxifen or aromatase inhibitors) to control the cancer. About 250 …
Phase 3 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for rare blood cancer: drug duo targets enlarged spleen
Disease control OngoingThis study tests whether adding the experimental drug navitoclax to the standard drug ruxolitinib can shrink the spleen and reduce symptoms better than other available treatments in adults with myelofibrosis that has returned or not improved. About 330 participants will be random…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Supercharged immune cells take on advanced cancers
Disease control OngoingThis early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …
Phase 1 • Sponsor: AgonOx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise for rare lung cancer subtype
Disease control OngoingThis phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Last-Resort drug access for rare lung cancer patients
Disease control Expanded access (ended)This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …
Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for advanced bowel cancer patients too frail for strong chemo
Disease control OngoingThis phase 3 study tests whether a combination of trifluridine/tipiracil (a chemotherapy pill) and bevacizumab (a targeted therapy) works better than the current standard of capecitabine plus bevacizumab for people with metastatic colorectal cancer who are not healthy enough for …
Phase 3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktail aims to fight advanced liver cancer
Disease control OngoingThis phase 3 study tests whether a combination of cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy) works better than the standard drug sorafenib for people with advanced liver cancer who haven't had prior systemic treatment. About 837 adults are taking part. …
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Radioactive therapy targets Hard-to-Treat cancers in new trial
Disease control OngoingThis phase 2 trial is testing a radioactive drug called 177Lu-PSMA in 83 people with advanced or metastatic cancers that show up on a PSMA PET scan. The drug is given intravenously every 8 weeks for up to 4 cycles. The main goals are to check safety and see if the treatment can c…
Phase 2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Canadian study monitors Venetoclax's Real-World impact on AML
Disease control OngoingThis study looks at how well the drug venetoclax works for adults with acute myeloid leukemia (AML) who cannot handle strong chemotherapy. About 210 people across Canada will take venetoclax pills daily as part of their normal care. Researchers will track their overall survival a…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug duo aims to stall advanced breast cancer
Disease control OngoingThis study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib in people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be foll…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug targets Hard-to-Treat cancers with MET mutations
Disease control OngoingThis early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…
Phase 1 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Precision radiation offers new hope for recurrent prostate cancer
Disease control OngoingThis study tests a focused radiation technique called HDR brachytherapy for men whose prostate cancer has come back after earlier radiation treatment. The radiation is placed directly into the cancerous area and removed after a short time, aiming to spare healthy tissue. The tria…
Sponsor: Loyola University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New triple therapy aims to stall advanced kidney cancer
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug cabozantinib to two immunotherapies (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer without their cancer growing. About 855 participants with intermediate- or poor-risk disease are randomly …
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 26, 2026 16:06 UTC
-
New drug cocktail targets hard-to-treat breast cancer
Disease control OngoingThis phase 2 trial is testing a combination of three drugs—atezolizumab, trastuzumab, and vinorelbine—in people with HER2-positive advanced or metastatic breast cancer that has already been treated with trastuzumab and other anti-HER2 therapies. The study focuses on patients whos…
Phase 2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 26, 2026 15:16 UTC
-
New drug duo aims to outsmart advanced melanoma
Disease control OngoingThis study tests whether adding a new immunotherapy drug, relatlimab, to the standard drug nivolumab works better than nivolumab alone for people with advanced melanoma that has spread or cannot be removed by surgery. About 714 participants who have not had prior treatment for th…
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 15:12 UTC
-
Brain cancer boost: radioactive tile added to standard therapy in new trial
Disease control OngoingThis study tests whether adding a special radiation tile (GammaTile) during brain surgery, followed by standard chemotherapy and radiation, is safe and feasible for people with newly diagnosed glioblastoma. About 61 participants will receive the tile implant at the time of tumor …
Phase 4 • Sponsor: GT Medical Technologies, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:19 UTC
-
Immunotherapy plus chemo shows promise in advanced uterine cancer trial
Disease control OngoingThis phase 3 study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 785 participants receive either dostarlimab …
Phase 3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:51 UTC
-
Blood thinner flush could boost tumor biopsy success
Diagnosis CancelledResearchers test whether flushing the biopsy needle with heparin, a blood thinner, helps collect more and better tissue from solid abdominal tumors during endoscopic ultrasound-guided fine needle biopsy. They also test whether using a microsieve to prepare the tissue improves the…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Light-Based probe aims to spot thyroid cancer faster
Diagnosis CancelledResearchers are testing a technique called Raman spectroscopy to see if it can accurately identify thyroid cancer in tissue samples. The study involves patients who are already having a routine thyroid biopsy for suspected cancer. After the biopsy, the removed tissue is examined …
Sponsor: Gloucestershire Hospitals NHS Foundation Trust • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Finger prick vs. needle: can a drop of blood replace the lab draw?
Diagnosis CancelledResearchers are testing whether a finger-prick blood testing device, the Entia Liberty System, gives accurate results compared with standard laboratory blood tests. Participants are adults receiving systemic anti-cancer therapy who already need routine full blood count tests. The…
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Can cancer patients test their own blood at home?
Diagnosis CancelledResearchers are studying whether the Entia Liberty, a home blood testing device, is easy and safe for cancer patients to use on their own. Participants are adults receiving systemic anti-cancer therapy who can read English and give consent. The trial measures how well patients op…
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
A new imaging agent aims to make solid tumors visible on PET scans
Diagnosis Expanded access (paused)This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…
Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
AI reads prostate scans to catch dangerous cancers and skip needless biopsies
Diagnosis CancelledResearchers at Northwestern University are testing an artificial intelligence tool that reads prostate MRI scans to find suspicious lesions. The goal is to see whether this AI can detect clinically significant prostate cancer as well as or better than the standard PIRADS scoring …
Sponsor: Northwestern University • Aim: Diagnosis
Last updated Aug 30, 2026 00:00 UTC
-
Can new tracers make many cancers light up on scans?
Diagnosis OngoingThis early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…
Early phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis By invitation onlyThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
New PET tracer may spot lung cancer tumors
Diagnosis PausedThis early-stage study is testing a radioactive imaging agent called [18F]-C-SNAT4 to see how it travels through the body and whether it can help detect lung cancer on PET scans. About 20 healthy volunteers and people with lung cancer will receive the tracer and undergo scans. Th…
Phase 1 • Sponsor: Stanford University • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis CancelledThis trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…
Sponsor: Jinling Hospital, China • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can AI be a Pathologist's second opinion?
Diagnosis By invitation onlyThis trial tests whether an AI tool called ENLIGHT can help pathologists more accurately and quickly distinguish between certain lung and kidney cancer subtypes. Pathologists will review digitized slides under three conditions: without AI, with AI as a double-check after their ow…
Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Finger-Prick test could replace needles for cancer blood monitoring
Diagnosis PausedThis study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Blood test could spot hidden cancers early in thousands
Diagnosis OngoingThis trial is testing a new blood test, called Galleri, that looks for signs of many different cancers. The goal is to see if adding this test to standard NHS screening helps find cancers at an early stage, when treatment is more likely to work. About 140,000 people aged 50-77 in…
Sponsor: GRAIL, Inc. • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Could a routine blood test spot many cancers early?
Diagnosis OngoingThis study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…
Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Hidden heart risk in cancer patients: simple ECG screening could save lives
Diagnosis OngoingThis study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Spit test could spot ovarian cancer earlier
Diagnosis OngoingThis study looks at whether RNA in saliva can help tell the difference between ovarian cancer, borderline tumors, and benign cysts. Researchers are collecting saliva samples from 746 women before and after surgery. The goal is to find a simple, non-invasive way to speed up diagno…
Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Simple blood test could transform cancer monitoring
Diagnosis OngoingThis study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…
Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New mammogram technique could spot breast cancer earlier in survivors
Diagnosis OngoingThis study tests whether contrast-enhanced mammography (CEM) finds breast cancer more accurately than standard mammography in women who have already had breast cancer. About 1,647 women ages 30-85 will get both types of mammograms to compare detection rates and false alarms. The …
Sponsor: Wendie Berg • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New scan may spare men from unnecessary prostate biopsies
Diagnosis OngoingThis study tests whether adding a PSMA PET scan helps doctors better diagnose significant prostate cancer in men whose MRI results are unclear or negative. About 660 men with no prior prostate cancer or biopsy will be randomly assigned to receive either standard care or an additi…
Phase 3 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
Blood test could spot hidden cancers in High-Risk patients
Diagnosis OngoingThis study is developing a blood test to find early-stage tumors in people with hereditary cancer syndromes (high genetic risk for cancer). Researchers will collect blood samples and medical data from about 1,400 participants across Canada. They will also interview patients and d…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
Can a smaller dose of a white blood cell booster protect cancer patients just as well?
Prevention By invitation onlyResearchers are studying whether a lower 3mg dose of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can prevent febrile neutropenia, a serious drop in infection-fighting white blood cells, in cancer patients after chemotherapy. The standard 6mg do…
Sponsor: Zhejiang Provincial People's Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Can electronic alerts and patient teaching stop deadly clots after cancer surgery?
Prevention OngoingBlood clots after major cancer surgery are common and dangerous, but patients often leave the hospital without medicine that lowers that risk. Researchers at the Medical University of South Carolina are testing whether educating surgeons and adding an electronic alert in the medi…
Sponsor: Medical University of South Carolina • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Game-Based app aims to boost HPV vaccination in young cancer survivors
Prevention OngoingThis trial tests whether a game-based mobile app can increase HPV vaccination among young cancer survivors. Participants use the app to learn about HPV risks and get reminders to complete the vaccine series. The study includes survivors aged 18-26 and caregivers of younger surviv…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Massive study tests if daily pills can ward off cancer and heart attacks
Prevention OngoingThis large study tested whether taking daily vitamin D3 and omega-3 (fish oil) supplements can lower the risk of developing cancer, heart disease, or stroke. Over 25,000 healthy older adults (men 50+, women 55+) took the supplements or placebos for about 5 years. The goal is to s…
Phase 3 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Aug 01, 2026 00:00 UTC
-
Massive norwegian study aims to slash colon cancer deaths with simple screening
Prevention OngoingThis large study is testing whether a screening procedure called flexible sigmoidoscopy can lower the number of colorectal cancer cases and deaths. About 100,000 men and women aged 50-64 in Norway are taking part. The study also looks at adding a stool blood test and how screenin…
Sponsor: Norwegian Institute of Public Health • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
Sidewalks and streetlights: a new weapon against cancer?
Prevention OngoingThis study tests whether making neighborhoods safer and more walkable—adding sidewalks, lighting, green spaces, and community programs—can reduce cancer risk in underserved areas. Researchers will measure stress levels and physical activity in 300 Black residents. The goal is to …
Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
Could a 4-Hour infusion replace 20 hours for neuroblastoma kids?
Symptom relief OngoingThis study tests if giving the drug dinutuximab over 4 hours or less is safe and practical for children with high-risk neuroblastoma. Currently, standard infusions take 10-20 hours and require a hospital stay. The goal is to see if a shorter infusion can be used in an outpatient …
Phase 2 • Sponsor: Children's Hospital Los Angeles • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can mindfulness ease cancer stress for latino families?
Symptom relief OngoingThis study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New shot aims to quiet chemo nerve pain
Symptom relief OngoingThis study tests an injected drug called Halneuron to see if it can safely reduce nerve pain caused by chemotherapy. About 240 adults who have nerve pain from platinum or taxane chemo will receive either Halneuron or a placebo shot. The goal is to measure pain relief, sleep, fati…
Phase 2 • Sponsor: Dogwood Therapeutics Inc. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Could a social media app help heal the emotional scars of cancer?
Symptom relief By invitation onlyThis trial tests whether a program designed to boost social connections can improve the social and emotional well-being of young adults who had cancer. Participants, aged 22-39 and diagnosed between 15-39, will receive a video and planning tools to encourage more in-person intera…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief OngoingThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New gel shields bowel during prostate radiation – could cut side effects
Symptom relief OngoingThis trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…
Sponsor: Boston Scientific Corporation • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Mouth device aims to keep Sore-Relief rinses where They're needed
Symptom relief CancelledResearchers are testing a new medical device called Bocaliner in people who have painful mouth sores caused by chemotherapy or radiation. The device is held in the mouth after using medicated mouthwashes, gels, or rinses, with the goal of keeping those treatments in contact with …
Early phase 1 • Sponsor: E2Bio Life Sciences, LLC • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a virtual stress program help working spouses care for cancer patients without burning out?
Symptom relief OngoingResearchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…
Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a Nine-Week group program help blood cancer patients grow through trauma?
Symptom relief OngoingResearchers in Greece are testing a nine-session group program called TRANSFORM for people who have finished treatment for blood cancers such as leukemia, lymphoma, and myeloma. The program combines teaching, reflection, coping exercises, and mindfulness to see whether it can spa…
Sponsor: University of West Attica • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a text message help depressed cancer survivors get the care they need?
Symptom relief OngoingDepression is common among cancer survivors, but many don't get help. This pilot study tests a text-based referral platform that sends tailored messages and a video to encourage survivors to take up a mental health referral. The study will enroll 60 cancer survivors with depressi…
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a Five-Session program help young cancer patients keep their friendships?
Symptom relief OngoingResearchers are testing a five-session program called PRISM-SN for people aged 12 to 25 who were recently diagnosed with cancer and are receiving chemotherapy or radiation. The program teaches skills for managing stress, setting goals, reframing negative thoughts, finding meaning…
Sponsor: Seattle Children's Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
AI predicts vomiting in young cancer patients to stop sickness before it starts
Symptom relief OngoingThis study tests whether a computer model can predict vomiting in children with cancer who are in the hospital. The model uses each child's medical information to estimate their risk of vomiting in the next 96 hours. Doctors and pharmacists will use this information to give extra…
Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Money worries in cancer care: new program aims to keep patients on track
Symptom relief OngoingThis study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Coloring and music may calm cancer screening fears
Symptom relief By invitation onlyThis trial tests whether a 20-minute session of mandala coloring while listening to slow instrumental music can reduce cancer fear and anxiety in women undergoing cancer screening. Women aged 30 to 65 attending a screening center will be randomly assigned to either the coloring a…
Sponsor: Agri Ibrahim Cecen University • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Free meals for kids with cancer: a recipe for relief?
Symptom relief OngoingThis study looks at whether providing free, healthy frozen meals to families of children with cancer is practical and helpful. About 30 children aged 12-17 and their parents will receive meals for 12 weeks during chemotherapy. The goal is to see if families find the meals easy to…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
Could neck adjustments relieve Cancer-Related fatigue?
Symptom relief CancelledThis trial tests whether six weeks of upper cervical chiropractic care can help adults who have finished cancer treatment but still struggle with chronic fatigue. The study focuses on whether such a trial is practical, looking at recruitment, adherence, and acceptability. Partici…
Sponsor: Life University • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
New app aims to boost Well-Being in cancer patients
Symptom relief OngoingThis study tests a digital program called MINDSET designed to help newly diagnosed cancer patients cope better with treatment. 440 participants will use either the program or a control, and complete questionnaires and blood tests. The goal is to see if the program improves physic…
Sponsor: Stanford University • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
New support program aims to ease emotional burden of advanced cancer
Symptom relief By invitation onlyThis pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…
Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
Can talk therapy for sleep beat cancer fatigue?
Symptom relief OngoingThis trial tests whether cognitive behavioral therapy for insomnia (CBT-I) can reduce cancer-related fatigue in breast cancer patients who also have chronic insomnia. Participants receive different doses of CBT-I, which focuses on changing sleep habits and thoughts. The study aim…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Could prehab training during chemo strengthen young cancer patients?
Symptom relief OngoingThis study tests whether a supervised strength and balance exercise program is feasible for children and teens undergoing chemotherapy for bone or soft tissue sarcoma in the lower leg. The goal is to see if this 'prehabilitation' can reduce muscle and bone weakening, and improve …
Sponsor: Technical University of Munich • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
New app aims to ease cancer symptoms for rural patients
Symptom relief PausedThis study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
New online program aims to ease pain for cancer survivors
Symptom relief OngoingThis study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Virtual reality headsets may calm cancer patients before radiation
Symptom relief By invitation onlyThis trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…
Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A digital bridge: could an online pathway ease depression in cancer care?
Symptom relief OngoingThis study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New app helps cancer patients fight financial toxicity
Symptom relief OngoingThis study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …
Sponsor: Lauren Hamel • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Mind over body: new film series aims to boost wellbeing in young cancer survivors
Symptom relief OngoingThis study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …
Sponsor: King's College London • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Can a meditation app fix sleep for blood cancer patients?
Symptom relief OngoingThis study looks at whether using the Calm meditation app for 10 minutes a day can help blood cancer patients who have trouble sleeping. Researchers will track sleep, mood, and inflammation in 276 participants over 20 weeks. The goal is to find a simple, drug-free way to improve …
Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Community health workers step in to boost palliative care for black cancer patients
Symptom relief By invitation onlyThis study tests whether adding a trained community health worker (CHW) to standard care can improve quality of life and advance care planning for African American patients with advanced cancer. 160 patients will either receive standard care or standard care plus CHW support. The…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Can a smartphone app ease cancer Survivors' stress? new trial aims to find out
Symptom relief OngoingThis study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …
Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Bringing the gym to the farm: could a tailored home workout beat cancer fatigue?
Symptom relief OngoingThis study tests whether a 12-week home exercise program, guided by telehealth check-ins, can reduce fatigue in cancer survivors living in rural Colorado. Participants follow a personalized plan of aerobic and resistance exercises, with intensity adjusted based on their progress.…
Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Testosterone gel trial aims to beat cancer fatigue in older men
Symptom relief OngoingThis study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…
Phase 2 • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Could a single doctor visit reduce cancer distress?
Symptom relief By invitation onlyThis study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…
Sponsor: Ellis Medicine • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Money worries in cancer care: new study tests financial coaching to ease the burden
Symptom relief OngoingThis study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could an herbal patch ease pain after cancer?
Symptom relief OngoingThis study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Cancer survivors find hope in Peer-Led Self-Management program
Symptom relief OngoingThis study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …
Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
New telehealth program aims to ease emotional burden of advanced cancer
Symptom relief By invitation onlyThis study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…
Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
No more hospital trips? video nutrition counseling tested for cancer weight loss
Symptom relief OngoingThis study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…
Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can exercising at home match gym sessions for cancer recovery?
Symptom relief OngoingThis study compares a 12-week digital home-based resistance exercise program to a supervised on-site program for cancer survivors who finished treatment up to 5 years ago. The main goal is to see which approach leads to better exercise adherence. Researchers will also measure eff…
Sponsor: Inland Norway University of Applied Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Exercise program aims to keep kids with cancer moving
Symptom relief OngoingThis study tests whether children and teens with cancer will stick with a personalized exercise program during their treatment. About 38 participants will be offered adapted physical activity sessions from diagnosis or relapse. Researchers will use questionnaires to find out what…
Sponsor: University Hospital, Grenoble • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Can a 4-Week Pre-Surgery boost cut complications in GI cancer surgery?
Symptom relief OngoingThis study tests whether a 4-week program of exercise, nutrition advice, and stress management before major gastrointestinal cancer surgery can reduce serious complications within 30 days after the operation. About 400 adult patients scheduled for elective GI cancer surgery will …
Sponsor: Università Vita-Salute San Raffaele • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Magic mushroom compound tested for Cancer-Related depression
Symptom relief OngoingThis study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…
Phase 2 • Sponsor: Sunstone Medical • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Music as medicine: new study tests tunes to tame chemo side effects
Symptom relief By invitation onlyThis study explores whether music therapy can reduce anxiety, fatigue, and other symptoms in women with breast cancer who are receiving chemotherapy. Twenty-four participants will take part in weekly group music sessions and use personalized playlists at home, alternating periods…
Sponsor: Istituto di Studi Superiori Musicali (ISSM) Conservatorio Antonio Vivaldi di Alessandria • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Spine adjustments tested as fatigue fix for cancer survivors
Symptom relief PausedThis pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…
Sponsor: Life University • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Cash for cancer care: $1,000 a month trial aims to ease financial burden
Symptom relief OngoingThis study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…
Sponsor: Meredith Doherty, PhD, LCSW • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Partnered exercise boosts health for hispanic cancer survivors and caregivers
Symptom relief OngoingThis study tests a 3-month strength training program designed for Hispanic prostate cancer survivors and their caregivers. Participants exercise together in remote group classes to improve physical and mental health. The goal is to see if the program is practical and helpful for …
Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Sound waves vs. bone pain: can ultrasound replace radiation?
Symptom relief OngoingThis study tests whether MR-guided focused ultrasound (MR-HIFU), alone or with standard radiotherapy, can better relieve pain from bone metastases than radiotherapy alone. About 216 adults with painful bone lesions will be randomly assigned to one of three groups. The goal is to …
Sponsor: UMC Utrecht • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Cooling mat may offer Drug-Free relief for cancer treatment hot flashes
Symptom relief By invitation onlyThis study tests whether a special cooling mat can reduce hot flashes and night sweats in people taking hormone therapy for breast or prostate cancer. About 40 participants will use the mat for 8 weeks and track their symptoms. The goal is to see if this simple, non-drug approach…
Sponsor: Sligo General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Could a simple referral to palliative care ease End-of-Life suffering for cancer patients?
Symptom relief OngoingThis study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…
Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Light therapy eases mouth sores and skin burns in 33,000 cancer patients
Symptom relief OngoingThis real-world study follows 33,000 cancer patients in France using the CareMin650™ device, which shines light on mouth sores and skin burns caused by chemotherapy or radiation. The goal is to see if this light therapy reduces the severity of these painful side effects. Research…
Sponsor: Centre Hospitalier de Valenciennes • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Could early palliative care before cancer surgery improve quality of life?
Symptom relief OngoingThis study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…
Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Can acupuncture with electricity ease cancer brain fog and fatigue?
Symptom relief OngoingThis study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Texts and trackers: new study aims to get young cancer survivors moving
Symptom relief OngoingThis study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…
Sponsor: AHS Cancer Control Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Home exercise boosts recovery in elderly cancer patients
Symptom relief OngoingThis study tests whether a personalized home exercise program can improve physical function and quality of life in people aged 75 and older with colorectal cancer who are having surgery. Participants receive weekly phone coaching on strength, balance, and breathing exercises from…
Sponsor: Hospital General Universitario Gregorio Marañon • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Can a smartphone app boost quality of life for young cancer patients?
Symptom relief OngoingThis study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Robotic surgery or radiation? new study compares which is better for throat cancer patients' quality of life
Symptom relief OngoingThis study compares two treatments for early-stage throat cancer: robotic surgery (TORS) or radiation therapy (IMRT). It looks at which one leads to better swallowing function and overall quality of life. About 138 adults with HPV-related throat cancer are taking part. The goal i…
Sponsor: Christian von Buchwald • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Could methadone ease agonizing mouth pain in kids after transplant?
Symptom relief PausedThis study tests whether adding methadone to usual morphine-based pain medicine reduces severe mouth pain in children aged 6–18 who are getting a stem cell transplant for leukemia, aplastic anemia, or similar conditions. The mouth pain is a common side effect of the chemotherapy …
Phase 3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Talking it out: team approach may ease tough cancer decisions
Symptom relief OngoingThis study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need…
Sponsor: Hospital Universitario San Ignacio • Aim: Symptom relief
Last updated Jun 26, 2026 16:52 UTC
-
Massive data collection aims to spark breakthroughs in blood disorders
Knowledge-focused By invitation onlyThis study gathers medical information from up to 10,000 people with blood or heart conditions, as well as stem cell donors, treated at the National Institutes of Health. Researchers will review participants' medical records, test results, and treatments to build a database for g…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gut bacteria may hold clues to why some cancer treatments work better
Knowledge-focused PausedResearchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…
Sponsor: Persephone Biosciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
MD anderson study seeks to improve care for asian cancer patients
Knowledge-focused OngoingThis study aims to understand what helps or hinders a positive experience for Asian patients being treated for cancer at MD Anderson. Researchers will survey former patients and healthcare providers to identify key factors. The goal is to use these insights to improve care and su…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could a frailty score predict which older cancer patients survive intensive care?
Knowledge-focused OngoingOlder adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Massive farm study tracks Pesticide-Cancer links for decades
Knowledge-focused OngoingThis study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive NCI study tracks thousands of cancer patients receiving standard care
Knowledge-focused By invitation onlyThis study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a phone app help childhood cancer survivors keep track of their health?
Knowledge-focused OngoingResearchers at the University of California, San Francisco are testing a mobile app built for survivors of childhood cancer and their caregivers. The app shows each person their treatment history and follow-up recommendations, and sends messages to help them learn about their dia…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive cancer screening trial aims to cut deaths
Knowledge-focused OngoingThis study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
When cancer blocks the airway, doctors lack a playbook. experts aim to write one.
Knowledge-focused By invitation onlyTumours in the head, neck, or chest can narrow or distort the airway, and standard difficult-airway guidelines offer little cancer-specific advice. This study asks an international panel of anaesthesiologists, intensive care doctors, lung specialists, head and neck surgeons, and …
Sponsor: Onco Critical Care Society • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track families to uncover Cancer's hidden causes
Knowledge-focused OngoingThis study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused By invitation onlyThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Community cancer Centers' testing practices under review
Knowledge-focused CancelledThis study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can group classes boost cancer prevention in High-Risk women?
Knowledge-focused OngoingThis study tests whether group education sessions can help medically underserved women and racial/ethnic minorities with BRCA 1 or 2 mutations follow recommended cancer surveillance and risk-reducing procedures. Thirty participants will attend 90-minute group classes via Zoom. Th…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused OngoingThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Early phase 1 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
50,000 samples to unlock secrets of hereditary tumors
Knowledge-focused CancelledThis study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
A digital guide aims to help latinx cancer patients navigate genomic testing decisions
Knowledge-focused OngoingResearchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risk…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Radiation study seeks samples, not a cure
Knowledge-focused By invitation onlyThis study collects blood and urine samples from 1,000 adults receiving radiation therapy for cancer. Researchers want to learn how radiation affects gene activity in white blood cells, damages red blood cells, and changes hormone levels. No new treatment is being tested—this is …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Researchers collect blood to solve mystery of drug side effects
Knowledge-focused By invitation onlyThis study collects blood samples from people already in other NIH clinical trials who are having or are expected to have serious side effects from their drugs. The goal is to measure drug levels in the blood to better understand why side effects happen. Up to 100 participants ag…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Cancer patients with COVID-19: new study tracks their journey
Knowledge-focused OngoingThis study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Simponi under the microscope: new registry tracks Long-Term risks in ulcerative colitis patients
Knowledge-focused OngoingThis registry follows 535 adults with moderate-to-severe ulcerative colitis who are taking or starting Simponi. Researchers will track serious side effects like infections, cancers, and pregnancy outcomes over time. The goal is to better understand the long-term safety of this me…
Sponsor: Janssen Biotech, Inc. • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Your genes may decide how well lung cancer drug works
Knowledge-focused OngoingThis trial studies whether small differences in genes affect how patients with small cell lung cancer respond to the chemotherapy drug etoposide and how severe its side effects are. Researchers will analyze DNA from 600 patients who take etoposide capsules, comparing two versions…
Phase 2/3 • Sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Cell collection study paves way for future cancer therapies
Knowledge-focused By invitation onlyThis study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
AI helps doctors remember what matters most to cancer patients
Knowledge-focused OngoingThis study tests whether an AI tool can accurately summarize serious illness conversations between doctors and cancer patients. Researchers will send these summaries to doctors caring for hospitalized patients with advanced cancer. The goal is to see if the summaries are accurate…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Your phone could predict your health: new study tracks childhood cancer survivors
Knowledge-focused OngoingThis study looks at whether data from smartphones and wearable devices can help predict future health problems in adults who survived childhood cancer. About 600 survivors will track symptoms, activity, sleep, and heart rate. The goal is to use this information to improve follow-…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Fatigue study seeks to unravel mystery of exhaustion
Knowledge-focused OngoingThis study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …
Sponsor: National Center for Complementary and Integrative Health (NCCIH) • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can we help parents make better choices for children with cancer?
Knowledge-focused OngoingThis study looks at how parents make treatment decisions when their child has relapsed neuroblastoma, a type of cancer. Researchers want to understand if parents' choices match their true preferences, and whether they feel regret or burden over time. By following 96 parents, the …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Can young cancer survivors regain everyday independence?
Knowledge-focused By invitation onlyThis study looks at how well children and teenagers who finished treatment for leukemia or non-Hodgkin lymphoma can perform everyday tasks like dressing, playing, and moving around. Participants will complete a questionnaire, an obstacle course, and a motor skills test to assess …
Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
A simple screening program could transform cancer aftercare
Knowledge-focused OngoingThis trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…
Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Hidden risk: could opioid misuse be overlooked in cancer care?
Knowledge-focused PausedThis study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
15-Year safety watch for cell therapy recipients
Knowledge-focused By invitation onlyThis study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …
Phase 1 • Sponsor: USWM CT, LLC • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused OngoingThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can we predict growth problems in childhood cancer survivors?
Knowledge-focused OngoingThis study looks at how childhood cancer and its treatment affect weight and height from birth into adulthood. Researchers will track body mass index and growth in over 12,000 patients and survivors across Europe. They aim to identify factors that lead to being underweight, overw…
Sponsor: Fabiën Belle • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Do blood thinners help or hurt when cancer meets a clot?
Knowledge-focused OngoingThis study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can natural remedies and cancer treatments mix safely? a new study investigates
Knowledge-focused OngoingThis study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Chatbot could help families of kids with cancer understand genetic risks
Knowledge-focused By invitation onlyThis study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
Knowledge-focused PausedThis study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…
Sponsor: Entia Ltd • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Blood test may one day personalize drug dosing after stem cell transplants
Knowledge-focused OngoingThis study collects blood and stool samples from people receiving a donor stem cell transplant to understand how their bodies process the drug cyclophosphamide. By identifying biomarkers, researchers hope to develop a blood test that could predict how well a patient will respond …
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Cancer clinics study how to spot Patients' hidden struggles
Knowledge-focused By invitation onlyThis study looks at how community cancer clinics screen for health-related social needs, like help with housing, food, or transportation. Researchers will work with 144 clinic staff to understand what helps or hinders screening. The goal is to create custom plans to make screenin…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Leftover blood samples could unlock new medical discoveries
Knowledge-focused By invitation onlyThis study collects leftover blood or tissue samples and related health data from people who have already had lab tests at LabCorp. The goal is to build a large, de-identified resource that scientists can use for future research on pregnancy, cancer, and infectious diseases. Some…
Sponsor: Sequenom, Inc. • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Artificial intelligence reads tissue samples in minutes to guide cancer surgery
Knowledge-focused OngoingThis study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New study tracks Cancer's genetic secrets during therapy
Knowledge-focused OngoingThis research study looks at how certain cancers (head and neck, esophagus, and anal canal) change at the genetic and immune level when patients receive chemotherapy or immunotherapy. About 39 people with advanced cancer will provide blood samples and tumor tissue over time. The …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
21,000 lymphoma patients join landmark study to uncover what really affects survival
Knowledge-focused By invitation onlyThis study follows 21,000 adults newly diagnosed with non-Hodgkin lymphoma to learn which factors—like genetics, lifestyle, and treatment—affect survival and quality of life. Researchers will track health outcomes over time without providing a new treatment. The goal is to improv…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Island hopping for cancer care: first study maps Survivors' journeys across six caribbean nations
Knowledge-focused By invitation onlyThis study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…
Sponsor: Vaughan A. Lewis Institute for Research and Innovation • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Light-Activated therapy shows promise for tumor control without surgery
Knowledge-focused OngoingThis study follows people who have received photodynamic therapy (PDT) for various cancers, including head and neck, lung, and skin tumors. PDT uses a light-sensitive drug and a special light to destroy cancer cells while sparing healthy tissue. Researchers will review medical re…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Could your workout history affect your Cancer's genes?
Knowledge-focused OngoingThis study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Smartwatches for cancer survivors: a new way to track symptoms?
Knowledge-focused OngoingThis study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…
Sponsor: Laura Longshaw • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Massive study tracks 32,000 oil spill cleanup workers for hidden health risks
Knowledge-focused OngoingThis study follows over 32,000 people who helped clean up the 2010 Deepwater Horizon oil spill in the Gulf of Mexico. Researchers want to see if exposure to crude oil and chemical dispersants leads to long-term health problems like heart disease, cancer, or lung issues. Participa…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Math formula could help surgeons cut bone graft waste in tumor surgery
Knowledge-focused OngoingThis study tests whether a simple mathematical formula, applied to routine CT scans, can accurately predict the size of a bone defect that will be created during surgery to remove a bone tumor. Accurate prediction could help surgeons select the right-sized donor bone graft before…
Sponsor: Sakarya University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Unlocking the Body's energy secrets in advanced cancer
Knowledge-focused OngoingThis study explores how much energy people with incurable cancer actually use, compared to standard formulas. Researchers will measure resting energy expenditure using a special device and track survival over time. The goal is to improve nutritional care for these patients.
Sponsor: Norwegian University of Science and Technology • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Can coaching caregivers improve cancer Decision-Making?
Knowledge-focused OngoingThis study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Radiation combo aims to fight cancer without drugs – but study never started
Knowledge-focused CancelledThis study planned to test whether adding low-dose radiation to standard high-dose radiation could trigger an 'abscopal effect' – where untreated tumors also shrink. It was designed for adults with metastatic solid tumors. However, the study was withdrawn before any patients were…
Sponsor: Soonchunhyang University Hospital • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive UK study tracks cancer after organ transplants
Knowledge-focused OngoingThis study looks at why people who have had an organ transplant are more likely to get cancer. Researchers will combine existing health records from over 85,000 transplant patients in England to track cancer cases and deaths. The goal is to better understand risks and improve car…
Sponsor: University of Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Clinicians share insights to shape AI support for breast cancer patients
Knowledge-focused By invitation onlyThis study asks 12 clinicians in Florida who care for women with breast cancer about gaps in emotional and mental health support. They will join virtual focus groups and fill out a short survey. The goal is to use their insights to build an AI-powered digital platform called Mamm…
Sponsor: University of Central Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Genetic clues could personalize prostate cancer therapy
Knowledge-focused OngoingThis study looks at how genetic differences (SNPs) in prostate cancer patients affect their response and side effects to the drug abiraterone. Researchers will analyze DNA from 600 patients taking abiraterone plus prednisone and bicalutamide. The goal is to find genetic markers t…
Phase 2/3 • Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Blood test aims to catch hidden head and neck cancer early
Knowledge-focused OngoingThis study is testing whether a blood test can find tiny bits of tumor DNA (ctDNA) or HPV DNA in patients with high-risk head and neck cancer after standard treatment. The goal is to see if this test can detect cancer that remains or comes back earlier than usual scans. The study…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New screening tool aims to catch hidden need for palliative care in hospitals
Knowledge-focused OngoingThis study tests a questionnaire called NECPAL to see if it can spot patients with serious long-term illnesses like cancer, heart failure, or kidney disease who might benefit from palliative care. Researchers will check 200 adults in the hospital or day clinic to see how many are…
Sponsor: Infanta Leonor University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Cancer patients get help planning families in new study
Knowledge-focused OngoingThis study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can a website replace a genetic counselor? new study tests digital result delivery
Knowledge-focused OngoingThis study looks at two ways to share important genetic findings with people who joined a biobank. Some participants will get their results through a website or chatbot, while others will speak with a genetic counselor by phone or video. The goal is to see if the digital method w…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Withdrawn study sought to understand sinus problems in young cancer survivors
Knowledge-focused CancelledThis study aimed to find out how often chronic sinusitis occurs in children treated for head and neck cancer, and how it affects their quality of life. Researchers planned to compare these children to those treated for cancer elsewhere in the body using a questionnaire called SNO…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy safety check: 400 cancer patients monitored for years
Knowledge-focused By invitation onlyThis study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Cancer imaging study pulled before starting
Knowledge-focused CancelledThis study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…
Early phase 1 • Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Bone metastasis database study aims to improve patient quality of life
Knowledge-focused CancelledThis study collects medical information from patients whose cancer has spread to the bone. The goal is to learn more about how cancer affects bones and how to prevent complications like fractures and pain. No extra tests or visits are needed—just data from regular care. The study…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Massive cancer survival study launched in russia
Knowledge-focused OngoingThis study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…
Sponsor: N.N. Petrov National Medical Research Center of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
One workout could boost cancer fighters?
Knowledge-focused OngoingThis study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …
Phase 2 • Sponsor: Universität Duisburg-Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Major study aims to settle debate on best bladder cancer treatment
Knowledge-focused OngoingThis study compares two common treatments for recurrent non-muscle-invasive bladder cancer: medical therapy (drugs placed in the bladder) and surgery (bladder removal). Researchers will track quality of life and patient experiences in 570 adults to see which approach works better…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Patients claim cannabis stops tumor growth – scientists investigate
Knowledge-focused OngoingThis study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.
Sponsor: HealthPartners Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Spanish study tracks CLL Patients' Well-Being on standard oral therapies
Knowledge-focused OngoingThis study watches how people with chronic lymphocytic leukemia (CLL) feel and function while taking standard oral treatments. About 146 adults in Spain will fill out questionnaires about their symptoms, fatigue, and worries during routine doctor visits. No new drugs are given—th…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a Men's cancer support program fit into routine care?
Knowledge-focused OngoingThis study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…
Sponsor: University College Cork • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Smartwatches track cancer symptoms at home
Knowledge-focused By invitation onlyThis study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy DNA test may spot cancer in Moms-to-Be
Knowledge-focused By invitation onlyThis study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New Full-Body PET scanner promises faster scans, less radiation
Knowledge-focused OngoingThis study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
10-Year registry to track safety of weekly growth hormone in kids
Knowledge-focused By invitation onlyThis 10-year observational study will follow 500 children with growth hormone deficiency who are receiving the once-weekly injection somapacitan as part of their routine care. Researchers will track side effects, medication errors, and new cases of cancer or type 2 diabetes. The …
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused OngoingThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Nuts vs. disease: Million-Person study seeks answers
Knowledge-focused OngoingThis study looks at data from 1 million adults worldwide to see if eating nuts is linked to a lower risk of diseases like diabetes, heart disease, cancer, and dementia. Researchers will combine information from many past studies to get clearer answers. The goal is to understand i…
Sponsor: Institut Investigacio Sanitaria Pere Virgili • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Skin sensor could alert doctors to rising pain in cancer and COPD patients
Knowledge-focused OngoingThis study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lab test could match cancer patients to the right drugs
Knowledge-focused OngoingThis study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…
Sponsor: China Medical University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Massive 10-Year health check: what happens when chronic diseases collide?
Knowledge-focused By invitation onlyThis study follows over 50,000 Chinese adults who were first surveyed between 2011 and 2014. Researchers will check how chronic lung, heart, metabolic diseases, and cancers have developed or changed over more than a decade. The goal is to understand how multiple health problems o…
Sponsor: China-Japan Friendship Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New MRI-Guided radiotherapy machine put to the test
Knowledge-focused OngoingThis study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Talking computer could revolutionize how cancer patients share symptoms
Knowledge-focused By invitation onlyThis study tests a friendly computer character that talks with cancer patients to help them report their symptoms more completely. About 100 adults with gastrointestinal or head and neck cancer who are getting chemotherapy or radiation will use this system. The goal is to see if …
Sponsor: Tufts Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
MRI-Guided radiation: a sharper weapon against cancer?
Knowledge-focused OngoingThis study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New app aims to close prostate cancer gap for black men
Knowledge-focused OngoingThis pilot study tests whether a smartphone app called Prostate Cancer Genius can help African American men learn about prostate cancer and complete a home-based PSA test. Eighty men aged 55 to 69 from Oklahoma who haven't had a PSA test in two years will use either the new app o…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can an online tool help older cancer patients stay connected to their care team?
Knowledge-focused OngoingThis pilot study tests whether elderly cancer patients (65 and older) can use an online tool to regularly report symptoms and quality of life during treatment. Over 3 months, patients fill out weekly questionnaires on side effects and two longer surveys on well-being. The goal is…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Can we track brain health in older cancer patients?
Knowledge-focused OngoingThis study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …
Sponsor: Our Lady's Hospice and Care Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Massive data hunt aims to unlock secrets of spine metastases
Knowledge-focused OngoingThis study is a registry that gathers detailed information from about 960 adults with metastatic spine tumors (cancer that has spread to the spine from elsewhere). Researchers collect data on patients' health, treatments, symptoms, and quality of life over time. The goal is to be…
Sponsor: AO Innovation Translation Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Million-Person african study aims to fill health data gap
Knowledge-focused OngoingThis study is gathering health information from one million people across Africa to better understand noncommunicable diseases like heart disease, cancer, and diabetes. Researchers are looking at risk factors such as weight, blood pressure, and smoking. The goal is to produce rel…
Sponsor: Alliance For Medical Research in Africa • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
7,000 tumor samples analyzed to uncover Cancer's hidden support system
Knowledge-focused OngoingThis study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Telehealth under the microscope: did virtual cancer care hold up during COVID?
Knowledge-focused By invitation onlyThis study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New scan could help spare healthy liver during cancer radiation
Knowledge-focused OngoingThis pilot study tests a special SPECT imaging scan called hepatobiliary scintigraphy to measure how radiotherapy changes liver function. Twenty adults with liver cancer will get the scan before and after radiation. The goal is to see if this method can show which parts of the li…
Sponsor: Royal North Shore Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New tech tracks breathing to zap lung tumors more precisely
Knowledge-focused OngoingThis study tests a new technology that adjusts the radiation beam in real time to follow lung tumors as they move with breathing. About 20 adults with early-stage lung cancer or limited lung metastases will receive standard radiotherapy with this tracking system. The main goal is…
Sponsor: Royal North Shore Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Italy launches massive genetic database to match cancer patients with better treatments
Knowledge-focused OngoingThis observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…
Sponsor: Federation of Italian Cooperative Oncology Groups • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
96,000 adventists help uncover Diet-Cancer links
Knowledge-focused OngoingThis study follows over 96,000 Seventh-day Adventists in the U.S. and Canada to see how diet and lifestyle choices relate to breast, colorectal, and prostate cancer. Researchers are focusing on intakes of meat, soy, and dairy. Because it is observational, it can show patterns but…
Sponsor: Loma Linda University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Withdrawn study sought to understand when lymphoma and cancer strike together
Knowledge-focused CancelledThis study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Pandemic delays led to fewer cancer diagnoses, study of 438,000 cases shows
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…
Sponsor: Bavarian Cancer Registry • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Can a simple screening tool help cancer centers support families better?
Knowledge-focused OngoingThis study compares two strategies for helping pediatric cancer centers use the Psychosocial Assessment Tool (PAT), a questionnaire that identifies family emotional, social, and practical needs after a child's cancer diagnosis. Eighteen cancer programs across the U.S. are randoml…
Sponsor: Nemours Children's Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Can community navigation cut cancer delays? botswana trial aims to find out
Knowledge-focused OngoingThis study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Can laughter yoga and art therapy ease cancer distress?
Knowledge-focused By invitation onlyThis study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…
Sponsor: La Tour Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can talking to a Psycho-Oncologist make cancer doctors better at their jobs?
Knowledge-focused By invitation onlyThis study tests whether four one-hour supervision sessions with a psycho-oncologist can help oncology and hematology clinicians handle difficult patient interactions. The 62 participants are doctors or nurses who will discuss challenging cases and reflect on their feelings. The …
Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Experts unite to make cancer trial results easier to compare
Knowledge-focused OngoingThis study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Blood tests may spare breast cancer patients from unnecessary scans
Knowledge-focused OngoingThis study looks at whether simple blood tests can tell if a woman's metastatic breast cancer is stable, so she can skip some routine scans. About 97 women with ER-positive/HER2-negative cancer will give blood samples at each scan visit. The goal is to create a smart algorithm th…
Sponsor: The Christie NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Promising sarcoma combo study pulled before starting
Knowledge-focused CancelledThis study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS) in their tumors. Participants would have received pembrolizumab (immunotherapy) with or without olaparib (a DNA repair blocker) before surgery, followed by m…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
New online tool aims to help older cancer patients get better treatment plans
Knowledge-focused OngoingThis study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Scientists peek inside the gut to unlock immunotherapy mysteries
Knowledge-focused OngoingThis study looks at how cancer immunotherapy changes the immune cells in the gut. Researchers will take small tissue samples from the colon and blood samples before and during treatment in 38 patients. The goal is to better understand gut-related side effects, not to test a new d…
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Gut bacteria could be key to better cancer immunotherapy
Knowledge-focused OngoingThis study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Blood test could replace painful biopsies for cancer patients
Knowledge-focused OngoingThis study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…
Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Simple blood test may reveal how far cancer has spread
Knowledge-focused OngoingThis study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…
Sponsor: Çanakkale Onsekiz Mart University • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:18 UTC